Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC

June 3rd 2025

Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.

Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression

June 2nd 2025

Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.

Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 2nd 2025

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Sammons on the Efficacy of RLY-2608 Plus Fulvestrant in PIK3CA-Mutant HR+/HER2– Breast Cancer

June 2nd 2025

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.

Dr Chahoud on Early Efficacy With Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

May 31st 2025

Jad Chahoud, MD, MPH, MHA, shares early-phase data with zanzalintinib plus nivolumab with or without relatlimab-rmbw in previously untreated ccRCC.

Dr Bardia on Efficacy Data from the DESTINY-Breast06 Trial of T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer

May 29th 2025

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.

Oncolytic Immunotherapy Approaches Open Up Alternative Treatment Avenues After Progression on Anti–PD-1 Therapy in Melanoma

May 29th 2025

Nikhil Khushalani, MD, discusses the clinical potential of RP1 plus nivolumab in patients with PD-1–refractory melanoma as well as considerations regarding its use.

Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer

May 28th 2025

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Later-Line Treatment Gaps in Esophageal Adenocarcinoma Underscore Need for Continued Therapeutic Development, Multidisciplinary Care

May 28th 2025

Nataliya Uboha, MD, PhD, underscores the crucial role of molecular profiling for guiding first-line treatment approaches in esophageal adenocarcinoma.

Dr Tarantino on Directions for Prospective Research in HER2+ Metastatic Breast Cancer

May 27th 2025

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

Dr Bowman on Distinctions Between Disease Characteristics and Treatment Response in ccRCC vs Non-ccRCC

May 27th 2025

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

MZB1 TCR-Like CAR T-Cell Therapy Yields Antitumor Activity in Multiple Myeloma and Waldenström Macroglobulinemia

May 27th 2025

Elena Maroto-Martin, PhD, highlights the mechanism of action and efficacy of MZB1 TCR-like CAR T-cell therapy in multiple myeloma.

Treatment Gaps Persist in Advanced Melanoma as Trials Explore Options Beyond Standard Checkpoint and BRAF/MEK Inhibitors

May 27th 2025

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

Dr Tang on the Implementation of Metastasis-Directed Radiotherapy in Oligometastatic ccRCC

May 23rd 2025

Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.

Dr Patel on Ongoing Research With Subcutaneous Bispecific Antibodies in Frontline Follicular Lymphoma

May 23rd 2025

Vivek G. Patel, MD, discusses the potential advantages of subcutaneous bispecific antibodies that are being evaluated in frontline follicular lymphoma.

Dr Ip on the Limitations of Real-World CAR T-Cell Therapy Research in LBCL

May 23rd 2025

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

Dr Ghia on OS Outcomes With Ibrutinib/Venetoclax in CLL Relative to a Matched Healthy Population

May 23rd 2025

Paolo Ghia, MD, PhD, discusses the rationale for conducting an OS analysis of fixed-duration ibrutinib plus venetoclax in patients with CLL.

CHMP Recommends EU Approval of Obe-Cel for Relapsed/Refractory B-ALL

May 23rd 2025

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Mirdametinib Earns Positive CHMP Opinion for NF1-Associated Plexiform Neurofibromas

May 23rd 2025

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025

May 23rd 2025

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.